CLINICAL AND IMMUNOBIOCHEMICAL PREDICTORS IN THE DIAGNOSIS OF BRONCHIAL ASTHMA IN COMORBIDITY WITH TYPE 2 DIABETES MELLITUS

Authors

  • Fayzullaeva Nigora Yakhyaevna

    Head of the Laboratory of Experimental Immunology, Institute of Human Immunology and Genomics, Academy of Sciences of the Republic of Uzbekistan, DSc, Professor

    Author

  • Raufov Alisher Anvarovich

    Senior Researcher, Laboratory of Experimental Immunology, Institute of Human Immunology and Genomics, Academy of Sciences of the Republic of Uzbekistan, PhD

    Author

  • Kayumov Abrorjon Anvarovich

    Junior Researcher, Laboratory of Experimental Immunology, Institute of Human Immunology and Genomics, Academy of Sciences of the Republic of Uzbekistan

    Author

  • Mukhtorov Sherzod Murod ugli

    Junior Researcher, Laboratory of Autoimmune Conditions, Institute of Human Immunology and Genomics, Academy of Sciences of the Republic of Uzbekistan, PhD

    Author

Keywords:
bronchial asthma, type 2 diabetes mellitus, MMP-9, immunobiochemical markers, superoxide dismutase, oxidative stress, diagnostics.
Abstract

The aim of this study was to perform a comprehensive evaluation of clinical, laboratory, and immunobiochemical markers in patients with bronchial asthma (BA) combined with type 2 diabetes mellitus (T2DM). A comparative analysis of clinical manifestations, carbohydrate metabolism parameters, hemostatic system indices, and antioxidant defense was carried out. It was found that superoxide dismutase (SOD) activity in patients with comorbid pathology decreased to 1001.7 ± 75.4 pg/mL, which was 1.5 times lower than in the group with isolated bronchial asthma (1201.8 ± 68.2 pg/mL) (p < 0.05), indicating pronounced oxidative stress. At the same time, a significant increase in MMP-9 levels was observed: in BA patients it was 120.7 ± 2.25 ng/mL, while in patients with BA combined with T2DM it increased to 175.3 ± 3.23 ng/mL, exceeding control values (31.5 ± 1.23 ng/mL) by more than 5 times and those of isolated asthma by 1.45 times (p < 0.05). These findings indicate an important role of inflammatory and tissue remodeling processes in the pathogenesis of comorbid conditions. The obtained data confirm that metabolic and immunobiochemical alterations significantly contribute to the development of combined BA and T2DM and may be useful for improving early diagnosis and prognostic assessment.

References

1. Bose, S., Gorska, A., & co-authors. Biomarkers of Type 2 airway inflammation as predictors of asthma control loss. Allergy, Asthma & Clinical Immunology, 2020; 16: P.112–118. https://doi.org/10.1186/s13223-020-00463-9

2. Cojić, M. M., & colleagues. Data-driven cluster analysis of oxidative stress indices: superoxide dismutase and catalase in metabolic diseases. Oxidative Medicine and Cellular Longevity, 2021; 2021(5): P.7942716. https://doi.org/10.1155/2021/7942716

3. Cremades-Jimeno, L., Lopez, E., García-Valero, J., & Torrent, I. Prioritizing molecular biomarkers in asthma and related immune-mediated respiratory conditions. Frontiers in Immunology, 2021; 12: P.640791. https://doi.org/10.3389/fimmu.2021.640791

4. Haglund, J., Håkansson, K., Lundgren, J., & Bergqvist, A. Type 2 inflammation and cardiometabolic disease in asthma: a 35-year population-based cohort study. European Respiratory Journal, 2025; 65(4): P.1085–1094. https://doi.org/10.1183/13993003.01085-2024

5. Kleniewska, P., & co-authors. The link between dysbiosis, inflammation and oxidative stress in asthma: clinical implications. Nutrients, 2024; 17(1): P.16–24. https://doi.org/10.3390/nu17010016

6. Liu, Y., & co-authors. Reactive oxygen species in asthma: mechanisms and therapeutic perspectives. Frontiers in Immunology, 2025; 16(2): P.1021–1034. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306563

7. Luo, T., Song, L., Chen, H., Yang, J., & Li, W. Monocyte CCL2 signaling possibly contributes to the causal relationship between type 2 diabetes and asthma: multi-level analysis. Scientific Reports, 2025; 15: P.95039. https://doi.org/10.1038/s41598-025-95039-1

8. Melinte, O.E., & colleagues. Oxidative stress and risk factors in adult patients with asthma: relation to control levels. Journal of Clinical Medicine, 2025; 14(11): P.4007–4016. https://www.mdpi.com/2077-0383/14/11/4007

9. Mubanga, M., et al. Association between asthma and type 2 diabetes in a multi-ethnic population: a cross-sectional study. Thorax, 2025; 80(6): P.385–392. https://doi.org/10.1136/thorax-2024-231205

10. Narendra, D. K., Yuri, H., & co-authors. Asthma and hyperglycemia: exploring the interconnected pathophysiology. Diagnostics, 2024; 14(17): P.1869–1878. https://doi.org/10.3390/diagnostics14171869

11. Radzyukevich, YV, Nikolaevich, IV, Petrova, NA, & Sidorov, AK Impact of comorbidity of bronchial asthma and type 2 diabetes mellitus: expression and functional activity of TLR2 and TLR4 on peripheral blood cells. Life Sciences, 2023; 13(2): P.550–558. https://doi.org/10.3390/life13020550

12. Uppal, P., Zhang, Y., Williams, R., & Singh, A. Type 2 Diabetes Mellitus and Asthma: Pathomechanisms, Clinical Outcomes, and Therapeutic Opportunities. International Journal of Molecular Sciences, 2023; 24(18): P.10241–10258. https://doi.org/10.3390/ijms24182410

13. Visca, D., Smith, D., & co-authors. The relationship between diabetes and respiratory diseases: a review of mechanisms. Respiratory Medicine, 2018; 142: P.23–32. https://doi.org/10.1016/j.rmed.2018.04.002

14. Wen, J., Wang, C., Zhuang, R., Guo, S., Chi, J., et al. Blood glucose levels, inflammation, and mortality in asthmatic populations: a prospective cohort study. Journal of Epidemiology and Global Health, 2025; 15: P.80–88. https://doi.org/10.1007/s44197-025-00425-7

15. Wu, T. D., et al. Role of Glycemic Dysfunction in Asthma – Review. Journal of Allergy and Clinical Immunology: In Practice, 2020; 8(12): P.4013–4021. https://doi.org/10.1016/j.jaip.2020.07.023

Downloads
Published
2026-03-30
Issue
Vol. 2 No. 3 (2026)
Section
Articles
License
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

CLINICAL AND IMMUNOBIOCHEMICAL PREDICTORS IN THE DIAGNOSIS OF BRONCHIAL ASTHMA IN COMORBIDITY WITH TYPE 2 DIABETES MELLITUS. (2026). Eureka Journal of Health Sciences & Medical Innovation, 2(3), 293-309. https://eurekaoa.com/index.php/5/article/view/681